Congress Materials – Pulmonary Hypertension Association (PHA 2024)
2024 Pulmonary Hypertension Association | Aug 15-18 | Indianapolis, IN
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
A Qualitative Interview Study to Evaluate Single-tablet Combination Therapy (STCT) within a Phase 3 Pulmonary Arterial Hypertension (PAH) Clinical Trial – Interim Analysis
Davis S, Randall JA, Linder J, Rafalski J, Hughes M, Agustin Rodriguez A, Friberg M, Burbridge C
Delphi study investigating the clinical use of oral selexipag to treat pulmonary arterial hypertension (PAH)
Sheryl Wu , Gurinderpal Doad, Christina Benninger, Michelle Cho, Richard Perry, Daisy Bridge, Charlotte Oswald, Luis Val-Maranes, Paul Strachan
Expert consensus on patient engagement strategies and shared decision-making to improve patient outcomes in pulmonary arterial hypertension
John J. Ryan, Sandra Lombardi, Rajan Saggar, Melisa Wilson, Christina Benninger, Jenny Lam, Gurinderpal Doad, Michelle Cho, Medi Stone, Daisy Bridge, Richard Perry, Ashley Enstone, Holly Smith, Lisa Perrett, Michelle Han
Expert consensus to explore the use of telehealth and associated strategies to improve access to care for remote and underserved patients with pulmonary arterial hypertension
Susanne McDevitt, Martha Kingman, Lana Melendres Groves, Gabriela Gomez Rendon, Michelle Han, Christina Benninger, Sylvia Georgi, Medi Stone, Daisy Bridge, Richard Perry, Ashley Enstone, Holly Smith, Gurinderpal Doad, Jean Elwing
Managing patient expectations when treated with oral selexipag for pulmonary arterial hypertension (PAH): results from a Delphi consensus survey
Sheryl Wu , Gurinderpal Doad, Christina Benninger, Michelle Cho, Richard Perry, Daisy Bridge, Charlotte Oswald, Luis Val-Maranes, Paul Strachan
Patient preferences regarding the use of combination ERA+PDE5i for the treatment of pulmonary arterial hypertension: Results from a discrete choice experiment.
Melisa Wilson, Nicholas A Kolaitis, Martha Kingman, Gabriela Gomez Rendon, David Lopez, Mohammad Rahman, Carly J Paoli, Ashley Martin, November McGarvey, Abraham Lee, Sana Mirza, Lana Melendres-Groves
Prior authorization restrictiveness negatively impacts time to receipt of endothelin receptor antagonist therapy for pulmonary arterial hypertension
Murali Chakinala, Sumeet Panjabi, Jeremy Casorso, Safee Azam, Jennifer Malinowski, Emma Holler, Vishal Kapoor, Josh Meyers, Ronald J Oudiz
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.